Navigation Links
Oncolytics Biotech(R) Inc.'s Research Collaborators to Present Data on REOLYSIN(R) Clinical Trials at ASCO Conference
Date:5/14/2009

CALGARY, May 14 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) announced today that data from three clinical trials using REOLYSIN are scheduled to be presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will take place in Orlando, Florida May 29-June 2, 2009. The abstracts are available on the ASCO website today at www.asco.org.

    REOLYSIN poster presentations

    -   Dr. Monica Mita and colleagues are scheduled to deliver a poster
        presentation entitled "A Phase II Study of Intravenous (IV) Wild-Type
        Reovirus in the Treatment of Patients with Bone and Soft Tissue
        Sarcomas Metastatic to the Lung."

    -   Dr. Johann de Bono and colleagues are scheduled to deliver a poster
        presentation entitled "A Phase I Study of the Combination of
        Intravenous Reolysin (REO) and Gemcitabine (GEM) in Patients (pts)
        with Advanced Cancer."

    -   Dr. Sanjay Goel and colleagues are scheduled to deliver a poster
        entitled "Dose Escalation and Pharmacodynamic Study of Intravenous
        Administration of REOLYSIN, a Live Replication Competent RNA Virus in
        Patients with Advanced Solid Tumors."

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN, its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com

T
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014 OTC Markets ... Inc., a biotechnology company, on its approval to ... traded on OTCQX®, the best marketplace for established ... Group. Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... successful execution of its growth strategy and achievement ...
(Date:8/21/2014)... August 21, 2014 Gallus ... contract development and manufacturing organization (CMO) announced today ... Inc., an oncology company focused on the development ... to manufacture the anti-prostate specific membrane antigen (PSMA) ... candidate. Under the agreement the antibody will ...
(Date:8/20/2014)... history lessons often have it that American Indians largely ... chicken pox, influenza and tuberculosis brought to the New ... vary, about 20 million people lived in the Americas ... them were killed by European diseases., But new research ... University and Johannes Krause of the University of Tubingen ...
(Date:8/20/2014)... , Aug. 20, 2014  PAREXEL International Corporation (NASDAQ: ... be presenting at the Baird Healthcare Conference in New ... Chief Financial Officer, will be making a presentation on ... on Wednesday, Sept. 3, 2014. A live ... "Investors" section of PAREXEL,s website at www.PAREXEL.com ...
Breaking Biology Technology:OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3PAREXEL International To Present At Baird Healthcare Conference 2
... China, April 24 /Xinhua-PRNewswire-FirstCall/ -- China Sky One,Medical, ... (OTC Bulletin,Board: CSKI), a pharmaceutical company for external ... ("PRC"), today announced it,acquired Heilongjiang Haina Pharmaceutical Inc. ... laws of the PRC on April,18, 2008., ...
... announced today that Chairman and CEO Fred Hassan purchased,just ... 000 shares at,an average purchase price of $18.26 per ... intention to purchase these shares in,January, this investment in ... -- including ZETIA and VYTORIN --,and our late- stage ...
... 24 /PRNewswire/ - Aegera Therapeutics Inc. is very,pleased ... and,financial executives to its Board of Directors: Mr. ... Managers Limited, and Mr. Gary,Littlejohn, Managing Director of ... experience and networks will be,critical for Aegera as ...
Cached Biology Technology:China Sky One Medical, Inc. Acquires Heilongjiang Haina Pharmaceutical Inc. 2China Sky One Medical, Inc. Acquires Heilongjiang Haina Pharmaceutical Inc. 3Aegera Therapeutics welcomes two experienced executives to its board of directors 2
(Date:8/20/2014)... Area Lyme Foundation, which aims to make Lyme disease ... research published in an upcoming issue of the Elsevier ... The findings show that ticks that carry Lyme ... making the threat of Lyme disease year-round. The research ... Health (CDPH) Vector-borne Disease Section and University of California, ...
(Date:8/20/2014)... causes a burning spiciness that is irresistible to some, ... effect are using their findings to develop a new ... be caused by inflammation or other problems. They reported ... in clinical trials, in ACS, Journal of Medicinal ... decades ago, scientists had pegged a compound called capsaicin ...
(Date:8/20/2014)... of honeybees grows to about 4,000 members, it triggers ... building of a special type of comb used for ... from the Department of Neurobiology and Behaviour at Cornell ... reproductive cycle of honeybee colonies. The results are published ... Nature . , Reproduction isn,t always a honeybee ...
Breaking Biology News(10 mins):Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3Worker bees 'know' when to invest in their reproductive future 2
... and hunger could be large over the next 20 years, ... higher temperatures could significantly reduce yields of wheat, rice and ... people who subsist on less than $1 a day. The ... and drive many into poverty. But even as some ...
... The old balkanized approach to ocean management, in ... laws and administered by different agencies, has failed to ... a panel of international scientists says, and should be ... planning. The panel, organized by scientists from Duke ...
... biologists and ecologists propose ever-larger conservation areas in the ... it,s local people banding together with their community leaders ... efforts in many parts of the world., "When people ... sacrifice," says Patrick Christie, University of Washington associate professor ...
Cached Biology News:Global warming may hurt some poor populations, benefit others 2Global warming may hurt some poor populations, benefit others 3Global warming may hurt some poor populations, benefit others 4Marine spatial planning: A more balanced approach to ocean management 2Marine spatial planning: A more balanced approach to ocean management 3Marine spatial planning: A more balanced approach to ocean management 4Local social dynamics key to success of tropical marine conservation areas 2
... Kilo-Sequencing is designed to aid sequence analysis ... multiple cloning sites (MCS) of M13 phage ... vectors (pUC18/19). The kit is used to ... DNA, thereby progressively moving the primer binding ...
Applications: Immunohistochemistry, ISH, FISH, CISH....
Attachments: Clip bar for tubes 10 to 19 mm in diameter Overall Dimension Height IC: 6 (15.2) Overall Dimension Length IC: 18.5 (46.9) Overall Dimension Width IC: 4 (10.2)...
Request Info...
Biology Products: